BioTechniques is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Journal
    • Aims and scope
    • Journal archive
    • Editorial board
    • For authors
    • Your editors: what do we do?

    Follow us on social media

  • Current issue
  • News
    • Latest news
    • Tech news
    • Events news
    • Company news

    Follow us on social media

  • Multimedia
    • Downloadable eBooks
    • Infographics
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • Features
    • Interviews
    • Opinion
    • In Focus
    • Spotlights
    • Companies
    • New products
    • Events

    Follow us on social media

  • Topics
    • Analytical chemistry
      • Biochemistry
      • Bioengineering and biophysics
      • Cancer research
      • Careers and Publishing
      • Cell and tissue biology
      • COVID-19
      • CRISPR
      • Computational biology
    • Diagnostics and preclinical
      • Drug discovery and development
      • Imaging
      • Immunology
      • Lab design and machinery
      • Microbiology
      • Molecular biology
    • Nanomedicine
      • Neuroscience
      • PCR and sequencing
      • Plant and climate science
      • Proteomics
      • Veterinary science
      • Whole-genome studies

    Follow us on social media

  • Become a member
Rapid epigenomic classification of acute leukemia 18 days 21 hours 50 mins 54 secs REGISTER NOW!

Reversing Alzheimer’s symptoms in mice with axitinib treatment

8 Oct 2021
Written by Ryan Gilroy (Commissioning Editor)
Drug discovery and development Neuroscience News

Alzheimer's and chemotherapy

Axitinib restored memory and cognitive function in mice that display symptoms of Alzheimer’s disease.

University of British Columbia (Canada) researchers demonstrated restoration of both memory and cognitive function in mice that display symptoms of Alzheimer’s disease by treatment with axitinib, a common chemotherapy drug.

READ MORE ON NEURO CENTRAL NOW

Top content

  • Novel AI drug discovery tool predicts more accurate treatment ‘recipes’
  • Where AFM meets AI: profiling macrophage mechanophenotypes
  • Our top picks of ASHG 2025

Related tags

Alzheimer's Disease chemotherapy
Previous article Next article

Related articles

27 MAY 2025 NEUROSCIENCE

How does Alzheimer’s disease affect tissues other than the brain?

2 AUG 2022 LAB DESIGN AND MACHINERY

An algorithm for recognizing neurological conditions

21 MAR 2022 NEUROSCIENCE

What is a healthy lifestyle? How dementia prevalence is impacted by a subsistence lifestyle

14 DEC 2023 NEUROSCIENCE

Developing a blood-based biomarker panel for early screening of Alzheimer’s disease

30 DEC 2024 CELL AND TISSUE BIOLOGY

Microglia revealed as double agents in Alzheimer’s disease progression

18 JUL 2022 NEUROSCIENCE

How many carats does it take to diagnose dementia?

  • About BioTechniques
  • Advisory Board
  • Contact Us
  • Advertising
  • Permissions
  • Whitelist Emails
  • Press release policy
  • Accessibility
Contact
Contact Us
Office info

BioTechniques is powered by Taylor & Francis Group

BioTechniques, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom

Impact Factor 2.2 | CiteScore 2.0

  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2025 BioTechniques